Cancer Tumor Profiling Global Market Opportunities And Strategies To 2035

Cancer Tumor Profiling Market Definition

Cancer tumor profiling refers to the comprehensive molecular and genetic analysis of cancerous tissues to identify specific mutations, gene expressions, protein markers, epigenetic modifications and other biological characteristics associated with a tumor. It is used to characterize the molecular architecture of cancer and to guide clinical and research decision-making in oncology. The cancer tumor profiling market consists of sales by entities (organizations, sole traders and partnerships) of cancer tumor profiling that are used by oncologists, pathologists, molecular biologists, academic researchers, pharmaceutical and biotechnology companies and contract research organizations. It is applied at the time of initial diagnosis to classify tumor subtypes, during treatment selection to identify actionable targets, throughout therapy to monitor response or resistance and at recurrence to reassess tumor evolution.

Cancer Tumor Profiling Market Segmentation

The cancer tumor profiling market is segmented by cancer type, by technology, by process type, and by application.

By Cancer Type –
The cancer tumor profiling market is segmented by cancer type into:

• a) Lung Cancer
• b) Breast Cancer
• c) Colorectal Cancer
• d) Prostate Cancer
• e) Melanoma
• f) Ovarian Cancer
• g) Stomach Cancer
• h) Pancreatic Cancer
• i) Thyroid Cancer
• j) Other Cancer Types

The breast cancer was the largest segment of the cancer tumor profiling market segmented by cancer type, accounting for 26.8% or $4,011.8 million of the total in 2025. Going forward, the lung cancer segment is expected to be the fastest-growing segment in the cancer tumor profiling market segmented by cancer type, at a CAGR of 14.4% during 2025-2030.

By Technology –
The cancer tumor profiling market is segmented by technology into:

• a) Next-Generation Sequencing (NGS)
• b) Polymerase Chain Reaction (PCR)
• c) Immunohistochemistry (IHC)
• d) In Situ Hybridization (ISH)
• e) Microarray
• f) Other Technologies

The next-generation sequencing (NGS) market was the largest segment of the cancer tumor profiling market segmented by technology, accounting for 36.5% or $5,472.8 million of the total in 2025. Going forward, the immunohistochemistry (IHC) segment is expected to be the fastest-growing segment in the cancer tumor profiling market segmented by technology, at a CAGR of 15.4% during 2025-2030.

By Process Type –
The cancer tumor profiling market is segmented by process type into:

1. a) Genomics
2. b) Proteomics
3. c) Epigenetics
4. d) Other Types

The genomics market was the largest segment of the cancer tumor profiling market segmented by process type, accounting for 42.5% or $6,362.2 million of the total in 2025. Going forward, the epigenetics segment is expected to be the fastest-growing segment in the cancer tumor profiling market segmented by process type, at a CAGR of 15.6% during 2025-2030.

By Application –
The cancer tumor profiling market is segmented by application into:

1. a) Personalized Medicine
2. b) Diagnostics
3. c) Biomarker Discovery
4. d) Prognostics
5. e) Research Applications

The diagnostics market was the largest segment of the cancer tumor profiling market segmented by application, accounting for 36.0% or $5,384.1 million of the total in 2025. Going forward, the personalized medicine segment is expected to be the fastest-growing segment in the cancer tumor profiling market segmented by application, at a CAGR of 14.4% during 2025-2030.

By Geography - The cancer tumor profiling market is segmented by geography into:

o Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• Taiwan
o South East Asia
• Indonesia
o North America
• USA
• Canada
o South America
• Brazil
o Western Europe
• France
• Germany
• UK
• Italy
• Spain
o Eastern Europe
• Russia
o Middle East
o Africa

North America was the largest region in the cancer tumor profiling market, accounting for 43.6% or $6,534.8 million of the total in 2025. It was followed by Asia Pacific, Western Europe and then the other regions. Going forward, the fastest-growing regions in the cancer tumor profiling market will be Asia Pacific and North America where growth will be at CAGRs of 14.3% and 11.7% respectively. These will be followed by Western Europe and Eastern Europe where the markets are expected to grow at CAGRs of 11.1% and 10.7% respectively.

Cancer Tumor Profiling Market Competitive Landscape

Major Competitors are:

Illumina Inc.

Thermo Fisher Scientific Inc

F. Hoffmann-La Roche Ltd. (Foundation Medicine)

Caris Life Sciences Inc.

QIAGEN N.V.

Other Competitors Include:

Tempus AI Inc.

NeoGenomics Laboratories Inc.

Exact Sciences Corporation

Myriad Genetics Inc.

Veracyte Inc.

Pillar Biosciences

BGI Genomics

Burning Rock Dx

Berry Genomics

Novogene

AmoyDx

Foundation Medicine

Guardant Health

Myriad Genetics

Fujirebio

Sonic Healthcare

Sysmex Corporation

LSI Medience Corporation

BML Inc.

Roche Diagnostics

NGeneBio

Seegene Inc.

Macrogen Inc.

GC Genome Co. Ltd.

LabGenomics Co. Ltd.

Gene Solutions

SOFIVA Genomics

ICT Genomics

Pacific Edge

Exact Sciences Corporation

Agilent Technologies

Myriad Genetics

OmiCure

CeGaT GmbH

EDX Medical Group plc

Hedera Dx

DoMore Diagnostics

SOPHiA GENETICS

MetaCell s.r.o.

Genomed SA

Eurofins Genomics

Aignostics

Geneseeq Technology Inc.

OncoHelix

Boreal Genomics

Bio-Rad Laboratories Inc.

OncoDNA

Diagnósticos da América S.A.

Oncoclínicas Group

Biotecgen

ImmunityBio

Genoks

M42

GenCare

G42 Healthcare

Codex Center

Exact Sciences

Cancer Tumor Profiling Market Drivers

The key drivers of the cancer tumor profiling market include: Adoption Of Precision Oncology During the forecast period, the adoption of precision oncology is expected to be a key driver propelling growth in the cancer tumor profiling market. Precision Oncology is a personalized cancer treatment approach that uses an individual patient’s genetic, molecular and clinical information to design targeted therapies. Instead of applying a one-size-fits-all treatment, it identifies specific mutations, biomarkers and biological pathways driving a patient’s tumor growth. Cancer tumor profiling supports precision oncology by analyzing the tumor’s DNA (deoxyribonucleic acid), RNA (ribonucleic acid) and protein expression patterns to detect actionable genetic alterations. This detailed molecular insight enables clinicians to select targeted drugs, immunotherapies, or combination treatments that improve efficacy, reduce unnecessary toxicity and enhance overall patient outcomes. Therefore, Adoption Of Precision Oncology may drive the growth of the cancer tumor profiling market. The adoption of precision oncology growth contribution during the forecast period in 2025 is 2.5%.

Cancer Tumor Profiling Market Restraints

The key restraints on the cancer tumor profiling market include: Payer Skepticism And Policy Barriers During the forecast period, payer skepticism and policy barriers are significantly hampering the growth of the cancer tumor profiling market. Uncertain reimbursement landscapes and restrictive coverage policies discourage hospitals, oncology centers and diagnostic laboratories from widely adopting advanced genomic and molecular profiling tests. From a financial and operational perspective, inconsistent reimbursement approvals, high out-of-pocket costs for patients and prolonged claims adjudication processes create revenue unpredictability for test providers and healthcare institutions. In addition, stringent evidence requirements from insurers compel companies to invest heavily in clinical validation studies, health economic analyses and real-world evidence generation before achieving broad coverage. These reimbursement complexities, coupled with fragmented policy frameworks across regions, limit test volumes, slow integration into standard oncology care pathways and constrain expansion into community healthcare settings. As a result, cancer tumor profiling developers and service providers may face delayed commercialization timelines, cautious investment decisions and moderated market penetration despite strong scientific advancements and growing demand for precision oncology. Growth affected by payer skepticism and policy barriers the forecast period in 2025 is -2.0%.

Cancer Tumor Profiling Market Trends

Major trends shaping the cancer tumor profiling market include: Liquid Biopsy Multi-Gene Panel For Comprehensive Genomic Profiling Major companies operating in the cancer tumor profiling market are focusing on developing innovative solutions, such as liquid biopsy-based next-generation sequencing multi-gene panels with integrated molecular analytics, to enhance noninvasive tumor detection, real-time disease monitoring and precision oncology treatment selection. Liquid biopsy-based next-generation sequencing multi-gene panels with integrated molecular analytics enable the analysis of circulating tumor DNA in blood samples to identify mutations, genomic alterations and resistance markers across multiple cancer-related genes. For instance, in July 2025, NeoGenomics Laboratories, Inc., a US-based oncology diagnostics company, launched PanTracer LBx, expanding access to comprehensive genomic profiling with liquid biopsy. The test is designed to analyze circulating tumor DNA from blood samples using advanced next-generation sequencing technology. It enables detection of clinically actionable mutations across a broad panel of cancer-associated genes. Emergence Of Hybrid Capture-Based Comprehensive Oncology Sequencing Platforms Key companies operating in the cancer tumor profiling market are focusing on introduction innovative solutions, such as hybrid capture-based comprehensive oncology sequencing assays integrated with cloud-driven bioinformatics platforms, to enhance biomarker discovery, improve variant interpretation accuracy and support precision oncology workflows. Hybrid capture-based comprehensive oncology sequencing assays integrated with cloud-driven bioinformatics platforms enable broad genomic interrogation of tumor samples to detect mutations, copy number alterations, structural variants and other clinically relevant changes. For instance, in November 2024, Sophia Genetics SA launched MSK-IMPACT powered with SOPHiA DDM at AMP 2024. The solution combines the well-established MSK-IMPACT comprehensive tumor profiling assay with the SOPHiA DDM™ cloud-based analytics platform to enhance genomic data analysis and interpretation. It enables detection of a wide range of somatic alterations across hundreds of cancer-associated genes. The integrated platform supports standardized reporting, advanced variant classification and scalable deployment across laboratories.

Opportunities And Recommendations In The Cancer Tumor Profiling Market

Opportunities – The top opportunities in the cancer tumor profiling market segmented by cancer type will arise in the breast cancer segment, which will gain $3,217.9 million of global annual sales by 2030. The top opportunities in the cancer tumor profiling market segmented by technology will arise in the next-generation sequencing (NGS) segment, which will gain $5,322.7 million of global annual sales by 2030. The top opportunities in the cancer tumor profiling market segmented by process type will arise in the genomics segment, which will gain $6,362.2 million of global annual sales by 2030. The top opportunities in the cancer tumor profiling market segmented by application will arise in the diagnostics segment, which will gain $5,384.1 million of global annual sales by 2030. The cancer tumor profiling market size will gain the most in the USA at $4,429.7 million. Recommendations- To take advantage of the opportunities, The Business Research Company recommends the cancer tumor profiling companies to focus on expanding liquid biopsy based genomic profiling and clinical adoption, focus on integrated hybrid capture sequencing platforms, focus on integrated multi-gene genomic profiling adoption, focus on integrated genomic profiling and evidence based decision support, focus on lung cancer tumor profiling for high growth precision oncology demand, expand in emerging markets, continue to focus on developed markets, focus on expanding distribution channels in place strategy, focus on value aligned pricing and reimbursement optimization in oncology diagnostics, focus on physician-centric evidence-based education, focus on multi-channel stakeholder digital outreach, and focus on clinical capability and stakeholder engagement in tumor profiling adoption.